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What’s new? 
 The N-terminus of glutamate decarboxylase (GAD65) contributes little to epitopes recognized 
by Type 1 diabetes associated GAD antibodies. 
 Radioimmunoassays using N-terminally truncated 35S-GAD65(96–585) improve the specificity 
of GAD antibody measurement. 
 We show that using a more radically truncated 35S-GAD65(143–585) radiolabel to measure 
GAD antibodies does not impact assay sensitivity and improves diabetes specificity 
compared with full-length 35S-GAD65(1–585).  
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 Relatives of people with Type 1 diabetes who were GAD antibody-positive using truncated 
radiolabels had increased risk of progression to diabetes within 15 years compared with 
those positive for GAD(1–585) antibody alone, and were at similar risk to those found 
positive using a high-performing commercial GAD antibody enzyme-linked immunosorbent 
assay. 
 
Abstract 
Aims Glutamate decarboxylase (GAD) antibodies are the most widely used predictive marker for 
Type 1 diabetes, but many individuals currently found to be GAD antibody-positive are unlikely to 
develop diabetes. We have shown previously that radioimmunoassays using N-terminally truncated 
35S-GAD65(96–585) offer better disease specificity with similar sensitivity to full-length 
35S-GAD65(1–
585). To determine whether assay performance could be improved further, we evaluated a more 
radically truncated 35S-GAD65(143–585) radiolabel. 
 
Methods Samples from people with recent-onset Type 1 diabetes (n = 157) and their first-degree 
relatives (n = 746) from the Bart’s–Oxford family study of childhood diabetes were measured for 
GAD antibodies  using 35S-labelled GAD65(143–585). These were screened previously using a local 
radioimmunoassay with 35S-GAD65(1–585). A subset was also tested by enzyme-linked 
immunosorbent assay (ELISA), which performs well in international workshops, but requires 10 
times more serum. Results were compared with GAD antibody measurements using 35S-GAD65(1–
585) and 35S-GAD65(96–585).  
 
Results Sensitivity of GAD antibody measurement was maintained using 35S-GAD65(143–585) 
compared with 35S-GAD65(1–585) and 
35S-GAD65(96–585). Specificity for Type 1 diabetes was 
improved compared with 35S-GAD65(1–585), but was similar to 
35S-GAD65(96–585). Relatives found to 
be GAD antibody-positive using these truncated labels were at increased risk of diabetes progression 
within 15 years, compared with those positive for GAD(1–585) antibody only, and at similar risk to 
those found GAD antibody-positive by ELISA. 
 
Conclusions The first 142 amino acids of GAD65 do not contribute to epitopes recognized by Type 1 
diabetes-associated GAD antibodies. Low-volume radioimmunoassays using N-terminally truncated 
35S-GAD65 are more specific than those using full-length GAD65 and offer practical alternatives to the 
GAD antibody ELISA for identifying children at increased risk of Type 1 diabetes. 
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<H1>Introduction 
Approximately 80% of children diagnosed with Type 1 diabetes have glutamate decarboxylase 
antibodies [1]. This marker is used widely, both clinically and in research, to identify individuals at 
increased risk of Type 1 diabetes, assisting in diabetes diagnosis and as an inclusion criterion for 
therapeutic intervention trials [2]. 
 
Radioimmunoassays are traditionally used to measure GAD antibodies, although other methods 
including enzyme-linked immunosorbent assay (ELISA) [3], electrochemiluminescence [4] or 
luciferase immunoprecipitation system assays [5] are becoming increasingly popular. Despite well-
established harmonization programmes [6] and international proficiency workshops to standardize 
and improve GAD antibody measurement [7], many individuals testing positive for this antibody do 
not progress to diabetes [8]. A commercial bridging ELISA, although requiring more serum per test 
than radioimmunoassays (50 µl vs. 4 µl, respectively), consistently showed higher specificity in 
international workshops [9]. This improved specificity may be explained in part by reduced access of 
autoantibodies to the N-terminus of GAD65 in the ELISA configuration. The primary antigenic region 
of Type 1 diabetes-associated GAD antibody is found in the middle and C-terminus of GAD65; 
antibodies recognizing only the N-terminal region were not associated with progression to multiple 
islet autoimmunity or diabetes [10,11]. We therefore developed an N-terminally truncated GAD65 
radiolabel, 35S-GAD65(96–585), for use as tracer. Removing the first 95 amino acids, comprising the 
first three exons of GAD65 [12,13] increased the specificity of GAD antibody radioimmunoassays 
without loss of sensitivity, improving their workshop performance [11]. We also demonstrated that 
autoantibodies measured with this construct, in first-degree relatives (FDR) of people with Type 1 
diabetes, were more closely associated with diabetes risk [14]. Fewer than half of FDRs found 
positive for GAD65(96–585) antibodies by radioimmunoassay, however, were likely to develop 
diabetes within 25 years. 
 
To discover whether further N-terminal truncation could improve the specificity of GAD antibody 
measurement by radioimmunoassay, we evaluated several GAD65 constructs in which regions up to 
and including exon 6 were deleted (Fig. 1a,b). We also investigated how GAD antibody levels 
measured by radioimmunoassay with truncated GAD65 labels or by ELISA compared, and examined 
how positivity by each method contributed to the overall risk of developing diabetes. 
 
<H1>Methods 
<H2>Population 
<H3>Bart’s–Oxford family study 
Sera were available from the Bart’s–Oxford (BOX) family study. This population-based study was 
established in 1985 [15] and has recruited more than 3000 children with Type 1 diabetes diagnosed 
before the age of 21 years in the Oxford region of the UK, 76% of whom are still followed up. Today, 
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over 6000 FDRs of the probands have been recruited and followed prospectively for disease 
development by annual questionnaire. All families were tested for autoantibodies to insulin, full-
length GAD65 and islet antigen 2, using established local assays [16]. Those found to be antibody-
positive were also tested for autoantibodies to zinc transporter 8 (ZnT8) [17].  
 
<H3>Cohort for initial screening of the GAD65 constructs 
Initial evaluation of the sensitivity and specificity of the N-terminally truncated 35S-GAD65 constructs 
was performed using a panel of sera from 11 people with Type 1 diabetes and 25 BOX relatives 
previously found to be GAD65(96–585) antibody-positive [14]. These relatives were considered at 
low-risk of diabetes because, although GAD65(96–585) antibody-positive, they did not have any 
additional islet autoantibodies and had not progressed to diabetes during follow-up. The constructs 
tested with this panel included: GAD65(115–585), GAD65(143–585), GAD65(160–585), GAD65(188–585) 
and GAD65(242–585) (Fig. 1c). 
 
<H3>Cohorts for evaluating the performance of GAD(143–585) antibody 
 
Sera with sufficient volume from 157 people (94 male; median age 11.7 years, age range 1.3–20.9 
years) with recent-onset Type 1 diabetes (median duration 1 day, range −7 to 90 days) were selected 
at random from 613 participants [14] to determine the disease sensitivity of GAD antibody 
measurement using the N-terminally truncated 35S-GAD65 constructs (Table 1, Fig. 2a). 
 
To evaluate discrimination of risk of diabetes progression, sera were available from 282 (138 male; 
median age 31.4 years, range 1.3–57.4 years) of 283 FDRs previously found to be GAD antibody-
positive with the local radioimmunoassay (Table 1, Fig. 2b). 
 
Assay specificity was further evaluated by testing the first available sample from 463 FDRs (229 
male; median age 33.3 years, age range 1.4–57.3 years) who previously tested GAD65(1–585) 
antibody negative with the local radioimmunoassay. Samples were selected at random from 4187 
GAD antibody-negative individuals but were enriched with 33 of 179 individuals who developed 
diabetes during follow-up (Table 1, Fig. 2b) [14]. 
 
<H3>Cohorts for evaluating the performance of the GAD antibody ELISA 
Limited serum availability prevented ELISA testing of all samples, such that 81 of the 157 people with 
Type 1 diabetes (52%), 258 of the 282 GAD antibody-positive relatives (91%) and 418 of the 463 GAD 
antibody-negative relatives (90%) were tested for GAD antibodies by ELISA (Table 1; Figs S1 and S2). 
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Results obtained with 35S-GAD65(143–585) and ELISA were compared with previous GAD(1–585) and 
GAD(96–585) antibody measurements [14,16]. 
 
<H2>Autoantibody assays 
<H3>Radioimmunoassay  
Sera (2 µl, in duplicate) screened using the local GAD antibody assay [16] were remeasured using the 
National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) harmonized GAD antibody 
radioimmunoassay protocol [6]. The GAD65 antigens were encoded in the PCMVTNT plasmid vector 
(Promega, Madison, WI, USA). 35S-Methionine-labelled GAD65 tracers were synthesized using the TnT 
quick-coupled in vitro transcription/translation system (Promega). Results were converted to 
Diabetes and Kidney (DK) units/ml using a standard curve. In the 2017 Islet Autoantibody 
Standardization Program (IASP) workshop, the adjusted sensitivity at 95% specificity for GAD(1–585), 
GAD(96–585) and GAD(143–585) antibody assays was 74%, 80% and 82%, respectively.  
 
<H3>ELISA 
Sera (25 µl in duplicate) were measured for GAD antibodies by ELISA (RSR Ltd, Cardiff, UK), following 
the manufacturer’s instructions. In brief, divalent GAD antibodies in serum form bridges between 
GAD65 immobilized on the ELISA plate wells and biotinylated GAD65 in solution [3,16]. Quantification 
of bound GAD antibodies was achieved following addition of streptavidin peroxidase and the 
substrate 3,3′,5,5′-tetramethylbenzidine. Stop solution was added and the absorbance of the 
reaction mixture at 405 nm was read. Results were converted to NIBSC 97/550 units using the 
calibrators provided. 
 
<H3>Antibody thresholds 
Thresholds for the harmonized GAD antibody radioimmunoassays that used the three GAD65 
constructs investigated in detail were set at the 97.5th percentile of 221 healthy schoolchildren (Fig. 
2a) [18], equal to 13.5, 12.8 and 11.8 DK units/ml for 35S-GAD65(1–585), 
35S-GAD65(96–585) and 
35S-
GAD65(143–585), respectively. 
 
Because of limited serum availability, the threshold for the GAD antibody ELISA was set at the 97.5th 
percentile of 180 of the 221 healthy schoolchildren, equal to 6.0 NIBSC 97/550 units (Fig. S1). The 
equivalent thresholds were 12.9, 14.0 and 11.8 DK units/ml for the same samples when measured 
with 35S-GAD65(1–585), 
35S-GAD65(96–585) and 
35S-GAD65(143–585), respectively. 
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<H2>Statistical analysis 
Wilcoxon matched-pairs signed-ranked test was used to compare signal-to-noise ratios (SNRs) and 
McNemar’s test with Yate’s correction for comparing antibody status between constructs and assay 
formats. The Kaplan–Meier test was used for survival analysis and the Mantel–Cox log-rank test for 
comparing survival between groups. For all analyses, a two-tailed P-value of < 0.05 was considered 
significant. The partial area (90th percentile) under the curve (pAUC) of the receiver operating 
characteristic (ROC) with 95% confidence intervals (CI) was calculated assuming a nonparametric 
distribution of results using R software, version 3.2.2. Other statistical analyses were performed 
using GraphPad Prism version 6. 
 
<H1>Results 
<H2>Initial construct screening 
N-terminally truncated 35S-GAD65 constructs were screened in the initial evaluation (Fig. 1) to 
discover which were likely to offer the best discrimination between diabetes and non-progression. A 
SNR (                                ) was calculated using a negative standard included 
in all assays. The SNR of 35S-GAD65(143–585) in people with Type 1 diabetes was most comparable 
with that with 35S-GAD65(96–585). Furthermore, this construct had low background binding and gave 
a lower SNR in the low-risk relatives compared with 35S-GAD65(96–585), suggesting that 
35S-
GAD65(143–585) had the potential to improve GAD antibody specificity without reducing sensitivity. 
35S-GAD65(143–585) was, therefore, selected for detailed evaluation (Fig. 1d, Table S1). 
 
<H2>Sensitivity was maintained with GAD(143–585) antibody in people with Type 1 diabetes and 
high-risk GAD antibody-positive relatives 
Of 157 people with Type 1 diabetes, 127 (80%) were positive for GAD(1–585) antibodies, 127 (80%) 
for GAD(96–585) antibodies and 128 (82%) for GAD(143–585) antibodies, with 124 (79%) positive for 
all three specificities (Fig. 2a). Using ROC analysis, pAUC values were 0.077 (95% CI 0.071–0.083), 
0.076 (95% CI 0.069–0.081) and 0.077 (95% CI 0.071–0.082), for GAD(1–585), GAD(96–585) and 
GAD(143–585) antibodies, respectively (Fig. S3a). Sensitivity at 95% specificity (AS95) was 84% for all 
three constructs. 
 
Sensitivity was also similar in the 109 relatives who progressed to diabetes during follow-up and/or 
had autoantibodies to additional islet antigens (Table S2), with 102 (94%) positive for GAD(1–585) 
antibodies, 98 (90%) for GAD(96–585) antibodies and 100 (92%) for GAD(143–585) antibodies. 
Ninety-five (87%) of these high-risk relatives were positive for all three specificities. 
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<H2>Fewer GAD(1–585) antibody-positive relatives who had no additional islet autoantibodies 
and had not progressed to diabetes tested positive using truncated 35S-GAD65 constructs 
Of the 173 low-risk relatives, 156 (90%) were positive for GAD(1–585) antibodies compared with 108 
(62%) for GAD(96–585) antibodies (P < 0.0001) and 98 (57%) for GAD(143–585) antibodies 
(P < 0.0001). The proportion of these low-risk relatives found positive for GAD(143–585) antibodies 
was reduced compared with those positive for GAD(96–585) antibodies (P = 0.02) (Table S3).  
 
<H2>Truncated 35S-GAD65 constructs improved discrimination of diabetes risk 
In 258 relatives who tested GAD antibody-positive using the harmonized radioimmunoassay with 35S-
GAD65(1–585), the 15-year risk of diabetes was 26% (95% CI 20–32%). Within this group, positivity 
for GAD(96–585) and GAD(143–585) antibodies showed a similar ability to further stratify diabetes 
risk (P < 0.0001, for both). Nevertheless, positivity for GAD(143–585) antibodies did not improve 
discrimination of risk compared with GAD(96–585) antibodies. Individuals positive for GAD(96–585) 
antibodies had a 33% (95% CI 26–41%) risk of developing diabetes within 15 years, whereas 
individuals positive for GAD(143–585) antibodies had a 34% (95% CI 27–42%) risk (Fig. 3a). 
 
<H2>Sensitivities of the ELISA and radioimmunoassays in people with Type 1 diabetes and high-
risk individuals were similar 
The prevalence of GAD antibodies in the 81 people with Type 1 diabetes measured by ELISA (86%) 
was similar to that in the same individuals measured by radioimmunoassay (80% for all three 
constructs, P > 0.05 for all comparisons) (Table S4 and Fig S1). ROC analysis of these 81 people with 
Type 1 diabetes and 180 healthy schoolchildren, found the pAUC for GAD antibodies measured by 
ELISA was 0.084 (95% CI 0.076–0.091), compared with 0.077 for GAD(1–585) antibodies (95% CI 
0.069–0.085), 0.076 for GAD(96–585) antibodies (95% CI 0.066–0.085) and 0.077 for GAD(143–585) 
antibodies (95% CI 0.069–0.084) when measured by radioimmunoassay (P > 0.05 for all 
comparisons) (Fig. S3b). AS95 was 84%, 86%, 85% and 89% for GAD(1–585), GAD(96–585) and 
GAD(143–585) antibodies and the ELISA, respectively. 
 
Of 85 relatives who progressed to diabetes and/or had autoantibodies to additional islet antigens, 
74 (87%) were found GAD antibody-positive by ELISA compared with 78 (92%, P > 0.05), 71 (84%, 
P > 0.05) and 76 (89%, P > 0.05) found positive for GAD(1–585), GAD(96–585) and GAD(143–585) 
antibodies by radioimmunoassay, respectively (Table S4).  
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<H2>Fewer GAD(1–585) antibody-positive relatives who had no additional islet autoantibodies 
and had not progressed to diabetes tested positive using the ELISA 
Of the 173 low-risk GAD antibody-positive relatives, 77 (45%) retested positive by ELISA compared 
with 156 (90%, P < 0.0001) using 35S-GAD65(1–585), 105 (61%, P < 0.0001) using 
35S-GAD65(96–585) 
and 98 (57%, P = 0.0001) using 35S-GAD65(143–585) (Table S5). 
 
<H2>GAD antibody measurement using ELISA did not improve discrimination of risk compared 
with truncated 35S-GAD65 constructs 
In the 234 relatives positive for GAD(1–585) antibody tested for GAD antibodies by ELISA, risk of 
developing diabetes within 15 years was 21% (95% CI 16–28%; P < 0.0001). Within this group, 
positivity for GAD(96–585) and GAD(143–585) antibodies, as well as GAD antibodies measured by 
ELISA, further stratified risk of diabetes (P < 0.0001, for all comparisons). However, 15-year risk in 
these individuals was similar when measured by ELISA (31%, 95% CI 24–41%) or by 
radioimmunoassays using 35S-GAD65(96–585) (28%, 95% CI 21–36%) or 
35S-GAD65(143–585) (29%, 
95% CI 22–38%) (Fig. 3b). 
 
<H2>Relatives who previously screened GAD antibody negative 
Of 463 relatives who previously tested negative for GAD antibodies using the local 
radioimmunoassay, 12 (3%) retested positive for GAD(1–585) antibodies, seven (2%) for GAD(96–
585) antibodies and 13 (3%) for GAD(143–585) antibodies (P > 0.05 for all comparisons). Three 
samples were positive with all three truncated constructs (Fig. 2b). Within this subset, 33 relatives 
had progressed to diabetes. Of these, none were positive for GAD(1–585) antibodies, one (3%) was 
positive for GAD(96–585) antibodies and two (6%) for GAD(143–585) antibodies (Tables S2 and S3). 
 
Similar results were seen for the 389 GAD antibody-negative relatives who did not progress to 
diabetes during follow-up, as 11 (3%) were positive using the ELISA compared with eight (2%, 
P > 0.05) using 35S-GAD65(1–585), three (1%, P = 0.04) with 
35S-GAD65(96–585) and nine (2%, P > 0.05) 
with 35S-GAD65(143–585) (Table S5). Of the relatives who progressed, 29 were tested for GAD 
antibodies using ELISA; one (3%) of these was positive with ELISA, whereas a different sample (3%) 
was positive using 35S-GAD65(143–585) (Table S4). 
 
<H1>Discussion  
A similar proportion of people with Type 1 diabetes and relatives who progressed to diabetes were 
found positive for GAD antibodies with radioimmunoassays using 35S-GAD65(96–585) and 
35S-
GAD65(143–585) or full-length 
35S-GAD65, indicating that sensitivity was maintained using the 
N-terminally truncated GAD65 constructs. Furthermore, relatives positive for GAD antibodies using 
these truncated labels were at increased risk of progression to diabetes within 15 years compared 
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with those who retested positive for GAD(1–585) antibodies using the harmonized assay, and at 
similar risk to those found GAD antibody-positive using the commercial ELISA.  
 
This study benefits from the inclusion of many participants selected from a well-characterized, 
population-based family study with common assay thresholds set using a schoolchild cohort from 
the same geographical area. Although the relatives analysed were not followed from birth, and, 
therefore, may not be perfectly representative of the general population, they nonetheless provide 
a unique opportunity to study the relationship between the autoantibody response to GAD65 and 
diabetes development over a prolonged follow-up, extending up to 30 years. In addition, all samples 
from people with Type 1 diabetes were collected within 3 months of diagnosis, minimizing the 
likelihood of negative seroconversion. Furthermore, antibodies to the 35S-GAD65 constructs have 
been measured using standardized and validated radioimmunoassays, whose performance was 
assessed in international workshops [6,9,11]. Limitations of our study were that all samples were 
pre-screened using a local full-length GAD autoantibody radioimmunoassay and we were unable to 
test all samples by ELISA, because of inadequate serum volumes. A large cohort of GAD antibody-
negative relatives was included to address any resulting selection bias and help evaluate the 
performance of the different assays when used for primary screening. Overall, these attributes 
allowed a detailed evaluation of disease specificity and sensitivity.  
 
Studies using engineered GAD65 proteins or monoclonal antibodies demonstrated that GAD 
antibodies associated with Type 1 diabetes primarily target epitopes found in the middle and 
C-terminal domains of GAD65 [19–25]. Using GAD67/65 chimeras, the BABYDIAB study identified the 
primary GAD antibody epitope within GAD65 residues 96–444, with epitope spreading to the 
N-terminal region being common [26]. Another group using competition radioimmunoassays with 
recombinant Fabs of four GAD65-specific monoclonal antibodies, found that epitope spreading from 
the C-terminus (amino acids 483–585) and middle region (amino acids 195–365) to the N-terminus 
(amino acids 96–173) was associated with progression, while epitope reactivity was stable in low-risk 
individuals [27]. This approach was also used to characterize GAD antibody epitopes in a small 
selection of people with Type 1 diabetes or latent autoimmune diabetes of adults, FDRs and healthy 
individuals. Competition with a Fab recognizing amino acids 96–173 (DP-D) reduced median binding 
by 80%. In people with Type 1 diabetes, 3% were fully inhibited by DP-D and 62% partially, 
implicating these amino acids as contributors to a disease-specific epitope. Although this inhibition 
may be related to amino acids 143–173, the discrepancy with our findings could be explained by 
effects of Fab binding on other regions of the molecule. Of note, GAD antibody-positive samples 
inhibited by a Fab recognizing amino acids 308–365 also showed competition by DP-D (P = 0.006) 
[24]. 
 
We investigated a range of truncated constructs including GAD65(115–585), GAD65(143–585), 
GAD65(160–585), GAD65(188–585) and GAD65(242–585). Removal of amino acids up to position 188 
had only a small impact on binding in people with Type 1 diabetes compared with 35S-GAD65(96–
585), whereas truncation at position 242, comprising the first 6 exons, severely reduced binding in 
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sera from people with Type 1 diabetes. These findings suggest that truncations up to position 188 
are unlikely to disrupt folding of the major GAD antibody epitopes but confirm that residues 188–
242 are probably critically important to the integrity of diabetes-relevant epitopes [24,27]. Although 
antibody binding was reduced in low-risk samples using 35S-GAD65(160–585) and 
35S-GAD65(188–
585), critically, the poor SNRs seen with these constructs resulted from increased background 
binding. Consequently, 35S-GAD65(143–585) was selected for detailed evaluation. Overall, a small 
improvement in disease specificity, without a loss of sensitivity was seen with this construct when 
compared with 35S-GAD65(96–585), indicating that the first 142 amino acids do not make an 
important contribution to Type 1 diabetes-associated GAD antibody epitopes. Assays using more 
radically truncated GAD65 antigens could, therefore, offer alternatives to GAD65(96–585) for GAD 
antibody measurement.  
 
The commercial GAD antibody ELISA performed well, but did not offer significant improvements in 
discriminating risk of developing diabetes within 15 years, compared with radioimmunoassays using 
the truncated 35S-GAD65(96–585) or 
35S-GAD65(143–585) constructs. Improved specificity may be 
expected when re-assaying samples using a different method, as non-specific binding is less likely to 
be reproduced in a different assay format.  However, we found little evidence that the ELISA would 
identify additional progressors who screened negative by radioimmunoassay. Furthermore, the 
ELISA requires 50 µl serum per test, compared with only 4 µl for the radioimmunoassay. This is an 
important consideration, as GAD antibody seroconversion often occurs in early infancy, and 
therefore early childhood is considered the optimum age for population screening for Type 1 
diabetes. Capillary blood samples, which can facilitate population screening and recruitment to 
trials, typically yield < 100 µl serum [28,29]. Low-volume radioimmunoassays with a proven track 
record therefore provide a useful tool for Type 1 diabetes prediction. The flexibility of this method 
enables detailed epitope characterization using truncated GAD65 antigens and chimeras, which may 
help to further delineate the autoimmune response. Radioimmunoassay can also evaluate other 
autoantibody features, such as affinity, which may further discriminate risk in GAD antibody-positive 
individuals [10,30]. 
 
We have shown that individuals who are positive for GAD antibodies measured using truncated 35S-
labelled GAD65 constructs have a higher risk of developing diabetes compared with those positive for 
full-length GAD antibodies. Thus, positivity for GAD(96–585) or GAD(143–585) antibodies may be a 
useful inclusion criterion for therapeutic intervention trials, which target high-risk individuals. 
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FIGURE 1. (a) Schematic of the N-terminally truncated GAD65 constructs screened for improved 
radioimmunoassay specificity. (b) Exon map of the N-terminal region of GAD65 (from Matsukawa and Ueno 
[13]). (c) Schematic of the experimental design for the screening process. The initial evaluation panel was used 
to select the most promising truncated GAD construct for more detailed comparison with GAD65(96–585). 
Samples with a range of GAD65(96–585) antibody titres were selected (median in people with diabetes: 421, 
range 159–1447 DK units/ml; median in relatives: 42, range 18–369 DK units/ml). (d) Signal-to-noise ratios 
(SNR) from 11 people with recent-onset Type 1 diabetes () and 25 single GAD(96–585) antibody-positive 
relatives who had not developed diabetes during follow-up (), measured for GAD antibodies using 35S-
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GAD65(96–585), 
35
S-GAD65(115–585), 
35
S-GAD65(143–585), 
35
S-GAD65(160–585), 
35
S-GAD65(188–585) and 
35
S-
GAD65(242–585) by radioimmunoassay. The SNR was calculated using a negative standard included in all assays 
(                                ). Bars represent the median and interquartile range of values. 
Differences in the SNRs of people with Type 1 diabetes compared with relatives who were diabetes-free shows 
discrimination of diabetes and non-progression. 
 
FIGURE 2. Selection scheme of samples tested for GAD antibodies using radioimmunoassay or ELISA, showing 
radioimmunoassay results for (a) healthy schoolchildren and people with recent-onset Type 1 diabetes or (b) 
BOX relatives. Samples were re-assayed with the NIDDK harmonized radioimmunoassay protocol using 
35
S-
GAD65(1–585), 
35
S-GAD65(96–585) and 
35
S-GAD65(143–585), and a proportion assayed using ELISA. Similar 
numbers of patients were found to be positive for GAD antibodies using all three radiolabelled constructs. 
Fewer relatives who were found previously to be GAD antibody-positive using a local assay were positive on 
re-assay for GAD(96–585) or GAD(143–585) antibodies compared with GAD(1–585) antibodies (P < 0.0001, for 
all). 
 
FIGURE 3. (a) Kaplan–Meier survival curve for 258 first-degree relatives found positive for GAD(1–585) 
antibodies in the harmonized assay, according to positivity for GAD(96–585) and GAD(143–585) antibodies. 
GAD(96–585) and GAD(143–585) antibodies identified relatives at increased risk of diabetes progression. 
Individuals positive for GAD(96–585) antibodies had a 33% (95% CI 26–41%) risk of developing diabetes within 
15 years, whereas those positive for GAD(143–585) antibodies had a 34% (95% CI 27–42%) risk. Few relatives 
who were positive for GAD(1–585) antibodies, but negative for GAD(96–585) or GAD(143–585) antibodies 
developed diabetes within 30 years of follow-up. (b) Kaplan–Meier survival curve for 234 first-degree relatives 
positive for GAD(1–585) antibodies according to positivity for GAD(96–585) and GAD(143–585) antibodies 
measured by radioimmunoassay and GAD antibodies measured by ELISA. These relatives are a subset of the 
cohort analysed in (a). Measurement of GAD antibodies using 
35
S-GAD65(96–585), 
35
S-GAD65(143–585) and the 
ELISA method identified relatives at increased risk of diabetes progression (P < 0.0001, respectively). 
Individuals positive for GAD(96–585) antibodies had a 28% (95% CI 21–36%) risk of developing diabetes within 
15 years, whereas those positive for GAD(143–585) antibodies had a 29% (95% CI 22–38%) risk and individuals 
found positive using ELISA had a 31% (95% CI 24–41%) risk. Few relatives who were positive for GAD(1–585) 
antibodies but negative for GAD(96–585) and GAD(143–585) antibodies or by ELISA developed diabetes within 
30 years of follow-up. 
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35S-GAD65(143–585). 
Table S4. GAD antibody levels in high-risk BOX samples measured with 35S-GAD65(1–585), 
35S-
GAD65(96–585) and 
35S-GAD65(143–585) in RIA and GAD65(1–585) in ELISA. 
Table S5. GAD antibody levels in low-risk BOX samples measured with 35S-GAD65(1–585), 
35S-
GAD65(96–585) and 
35S-GAD65(143–585) in RIA and GAD65(1–585) in ELISA.  
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Table 1 Characteristics of people with Type 1 diabetes and first-degree relatives participating in the BOX family 
study whose samples were originally screened for glutamic acid decarboxylase (GAD) antibodies using a local 
radioimmunoassay and were retested using 
35
S-GAD65(1–585), 
35
S-GAD65(96–585) and 
35
S-GAD65(143–585) by 
harmonized radioimmunoassay and GAD65(1–585) using an ELISA  
 People with 
Type 1 
diabetes 
(n = 157) 
GAD antibody-positive relatives 
(n = 282) 
GAD antibody-negative relatives 
(n = 463) 
Progressor 
(n = 72) 
Non-
progressor 
(n = 210) 
Progressor 
(n = 33) 
Non-
progressor 
(n = 430) 
No. of males (%) 94 (60) 36 (50) 102 (49) 24 (73) 205 (48) 
Median age, years 
(range) 
11.7 (1.3–
20.9) 
32.5 (1.6–
52.9) 
30.9 (1.33–
57.4) 
39.1 (1.4–
56.2) 
32.6 (1.7–
57.3) 
Median age at 
diagnosis, years 
(range) 
11.8 (1.3–
20.9) 
38.9 (3.2–
69.8) 
– 52.0 (3.3–
68.5) 
– 
Median follow-up, 
years 
1 7.4 17.6 12.4 7.6 
Median diabetes 
duration, days 
(range) 
−7 to 90 0.2–27.8 0.6–30.8 1.2–23.8 0–31.0 
Additional 
autoantibodies* 
142 41 37 5 11‡ 
Islet antigen 2 
antibodies 
122 24 13 2 1 
Indole 3 acetic acid 71† 23 23 4 10 
ZnT8A 113 30 17 1 - 
No. tested for GAD 
antibodies using 
ELISA (%) 
81 (52) 53 (74) 205 (98) 29 (88) 389 (90) 
ELISA, enzyme-linked immunosorbent assay (RSR Ltd, Cardiff, UK). 
*Additional autoantibodies are from islet antigen 2, indole 3 acetic acid and zinc transporter type 8.  
†57 not tested for indole 3 acetic acid as the sample was taken more than two weeks after diagnosis of Type 1 
diabetes and any antibodies measured may be to endogenous insulin induced by insulin therapy. 
‡Not tested for zinc transporter type 8. 
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